Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetics of Cotadutide in Participants With Hepatic Impairment

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant must be ≥ 18 to ≤ 85 years of age at the time of signing the Informed Consent Form (ICF).~* Body mass index ≥ 18 kg/m2 to \< 40 kg/m2.~* Female participants of childbearing potential must use at least one highly effective form of birth control.~* Capable of giving signed informed consent.~Participants with hepatic impairment only~- Diagnosis of chronic (≥ 6 months) and stable hepatic impairment (eg, no clinically significant change in signs, symptoms, or laboratory parameters of hepatic disease status within 30 days prior to study Screening).~Exclusion Criteria:~All participants~* History of severe allergy/hypersensitivity or ongoing clinically important allergy/hypersensitivity, or history of hypersensitivity to drugs with a similar chemical structure or class to cotadutide.~* Any clinically important abnormalities in rhythm, conduction or morphology of the 12-lead resting electrocardiogram (ECG) and any clinically important abnormalities in the 12-lead ECG as considered by the Investigator that may interfere with the interpretation of QT interval corrected for heart rate using Fridericia's formula (QTcF), including abnormal ST-T-wave morphology, or left ventricular hypertrophy~  1. Prolonged QTcF \> 470 ms or family history of long QT syndrome.~ 2. PR (PQ) interval shortening \< 120 ms.~ 3. PR (PQ) interval prolongation (\> 220 ms) intermittent or permanent second or third degree atrioventricular (AV) block, or AV dissociation.~ 4. Persistent or intermittent complete bundle branch block, or intraventricular conduction delay with QRS \> 119 ms.~* Any evidence of additional severe or uncontrolled systemic disease or laboratory finding that makes it unsafe for the participant to participate in the study.~* Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \< 30 mL/minute/1.73 m2 at Screening.~* Any positive result on Screening for serum hepatitis B surface antigen, anti-Core HBV antibody, hepatitis C antibody, or human immunodeficiency virus (HIV).~* Any sign and confirmation of coronavirus disease 2019 (COVID19) infection:~* Participants with concurrent or previous use of a glucagon-like peptide-1 (GLP1) receptor agonist.~* Use of prohibited prescribed or nonprescribed medication during the 2 weeks prior to the first administration of Investigational Medicinal Product (IMP) or longer if the medication has a long half-life.~* History of neoplastic disease within 5 years prior to Screening, except for adequately treated basal cell, squamous cell skin cancer, or in situ cervical cancer.~* Presence of hepatocellular carcinoma or acute liver disease caused by an infection or drug toxicity.~Participants with hepatic impairment only~* Severe portal hypertension or surgical porto-systemic shunts.~* Biliary obstruction or other causes of hepatic impairment not related to parenchymal disorder and/or disease of the liver.~* Clinically relevant hepatic encephalopathy.~* Severe ascites defined as ascites requiring paracentesis and albumin at 4-week intervals or less.~* Fluctuating or rapidly deteriorating hepatic function, as indicated by strongly varying or worsening of clinical and/or laboratory signs of hepatic impairment within the 28-day Screening period.~* Post liver transplantation.~* Platelet count \< 50 × 109/L and/or neutrophil count \< 1.2 × 109/L and/or hemoglobin \< 8.5 g/dL or INR \>2.3.~Participants with normal hepatic function only~* History or presence of hepatic disease or evidence of other known forms of known chronic liver disease.~* History or presence of gastrointestinal, hepatic, or renal disease, or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs.~* Urinary albumin-to-creatinine ratio \> 3 mg/μmol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- Cohort 1 (Type: EXPERIMENTAL): Participants in each cohort will receive Dose A cotadutide subcutaneously.
- Cohort 2 (Type: EXPERIMENTAL): Participants in each cohort will receive Dose A cotadutide subcutaneously.
- Cohort 3 (Type: EXPERIMENTAL): Participants in each cohort will receive Dose A cotadutide subcutaneously.
- Cohort 4 (Type: EXPERIMENTAL): Participants in each cohort will receive Dose A cotadutide subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy